Controlled Human Infection Challenge Studies which involve the deliberate infection of healthy volunteers are well established during the clinical development of vaccines for influenza, typhoid, cholera or malaria. Their aim is to accelerate clinical vaccine development by providing (preliminary) estimates of efficacy and safety and to select the most suitable candidates for further development. In addition, such studies have been used to better understand the immune response processes after infection.
These studies must be based on thorough ethical and scientific principles, and must involve careful community engagement. This webinar will describe these principles, outline the risk mitigation steps taken in previous malaria human challenge studies, explore how this might be applied in the context of COVID-19 vaccine development, and address ethical and practical concerns.
You can view the recorded webinar here: